Objective. Previous studies have demonstrated that the lower renal excretion of urates in patients with hyperuricaemia is inversely related to plasma very lowdensity lipoprotein (VLDL) levels, and the different genotypes of the apolipoprotein E gene are related to the plasma levels of lipids. The aim of this study was to determine the prevalence of apolipoprotein E in hyperuricaemic patients and to investigate whether the renal excretion of urates is conditioned by the apoliprotein E genotype. Method. The plasma levels of lipoproteins, cholesterol, triglycerides and uric acid, and the renal excretion of uric acid were studied in 68 patients with gout and in another control group of 50 healthy subjects. Both groups were genotyped for apolipoprotein E by means of an amplification technique and inverse hybridization. Results. The prevalence of the E2 allele was greater in the patients than in the control group. The levels of cholesterol, triglycerides and uric acid were greater in the patients, whereas the levels of high-density lipoprotein were lower. The patients with the E2 allele had higher levels of triglycerides in VLDL and intermediate-density lipoproteins and a lower renal excretion of urates. Conclusions. These results show that the reduced renal excretion of uric acid in patients with gout is mediated by high levels of VLDL and by the high prevalence of the E2 allele of apolipoprotein E.
Hyperuricaemia is associated with glucose intolerance, dyslipaemia and hypertension, central characteristics of the metabolic syndrome w1x. Although many studies have been published concerning hyperuricaemia and hypertension, atherosclerosis and cardiovascular complications, the role of uric acid in cardiovascular disease is still a question of debate w1x. More so if it is considered that no study of the genetic markers of hyperuricaemia has been undertaken.
In patients with gout the concentrations of triglycerides, apolipoprotein B (ApoB) and apolipoprotein E (ApoE) are increased and the levels of cholesterol in high-density lipoproteins (HDL) are reduced. Hypertriglyceridaemia affects 50% of patients with gout. Furthermore, 90% of hyperuricaemic patients have reduced renal excretion of urates, and patients with both hyperuricaemia and hypertriglyceridaemia have a lower renal excretion of urates than normolipaemic persons w2x. A reduction in very low-density lipoprotein (VLDL) levels after a hypocaloric diet has been shown to raise the renal excretion of urates w3x.
ApoE is one of the principal components of VLDL, HDL and chylomicron remnants, and it plays an important role in the modulation of lipoprotein metabolism via the hepatic chylomicron receptor and VLDL w4-7x. Human VLDL in circulating blood, secreted from the liver as triglyceride-rich particles, contains ApoB-100 as the structural protein component and ApoE as the functional protein component w8x. ApoE, which binds avidly to heparan sulphate proteoglycans, facilitates efficient VLDL catabolism by endothelial cell-bound lipoprotein lipase w9x. Polymorphisms of ApoE were first described by Utermann et al. w10x in 1977, since when Zannis et al. w11x determined that ApoE exhibits three isoproteins (designated ApoE2, ApoE3 and ApoE4) encoded by the respective apoE alleles (apoE2, E3, E4). The phenotypes of ApoE are known to be associated with lipid metabolism. The products of apoE2 and E4 are functionally and metabolically different from the common form apoE3, the isoprotein ApoE2 is deficiently bound to its receptor, resulting in decreased catabolism of the triglyceride-rich lipoproteins, whereas ApoE4 is associated with increased clearance of these lipoproteins w12x. Other studies have related ApoE4 with a hyperresponse to the content of dietary fat in the concentrations of LDL cholesterol w13, 14x. Thus, it would appear important to determine the apoE genotypes as part of an investigation of the relationship between uric acid and lipids. The relationship between uric acid and lipids and between lipoproteins and renal excretion of uric acid could be partly explained by apoE genotypes.
In this study we determined the apoE genotypes in persons with gout. The aims were to evaluate the possible contribution of the apoE genotype to the lipid anomalies, especially hyperlipaemia, and to the renal excretion of urates.
Material and methods

Subjects
A total of 68 Caucasian patients with gout were studied. One week before the start of the study, allopurinol was withdrawn from those patients receiving treatment. Plasma levels of glucose, cholesterol, triglycerides, creatinine, HDL cholesterol, low-density lipoprotein (LDL) cholesterol and uric acid were measured. All patients who were found to have glycaemic figures indicative of type II diabetes after a basal glycaemic or an oral glucose tolerance test were excluded. Their height and weight were also measured, from which the body mass index was calculated (weight in kilograms divided by the square of the height in metres), as well as uric acid clearance and the excretory fraction of uric acid in 24-h urine samples and after a purine-free diet for 1 week.
The control group was composed of 50 healthy Caucasian persons, from the same geographical area as the patients, with cholesterol and triglyceride levels <2.28 mmolul and no history of gout.
DNA analysis
DNA was isolated from venous blood by the salting-out method. The polymerase chain reaction was used for amplification of genomic DNA and apoE genotyping was made with the commercial kit Inno-Lipa ApoE (Innogenetics N.V. Belgium), which is based on the principle of inverse hybridization w15x.
Laboratory analyses
The samples of venous blood were collected after a 12-h fast. The serum was separated by centrifugation at 2000 g for 15 min for the lipid and lipoprotein determinations. The VLDL was separated by ultracentrifugation at 55 000 rpm for 18 h at 78C with a 458 rotor (Beckman TLA 100.3). After separation of the VLDL, the density of the infranatant was adjusted to 1.300 guml by the direct addition of potassium bromide and saccharose, and the other lipoproteins were separated by density gradient centrifugation at 45 000 rpm for 22 h at 78C with a swingingbucket rotor (Beckman SW 60Ti). To visualize the position of the lipoprotein bands a small amount (25 ml) of saturated solution of Coomassie blue was added. The concentrations of cholesterol and triglycerides were determined in each isolated fraction by the methods of cholesterol oxidase-peroxidase and glycerol oxidase-peroxidase.
All the analytical parameters of uric acid, cholesterol, triglycerides and renal excretion urates were measured in an autoanalyser with colorimetric assays (Ecoline 25, Diagnostica Merck).
Statistical analysis
Data are expressed as the mean"standard deviation. Comparison between groups was made by Student's t-test for independent samples. The apoE genotypes were examined by x 2 . A value of P < 0.05 was considered as statistically significant. The study was authorized by the Hospital Carlos Haya Ethics Committee.
Results
Clinical characteristics of the subjects
The clinical characteristics and the biochemical values of the two study groups (control and hyperuricaemic patients) are summarized in Table 1 . The levels of cholesterol, triglycerides and plasma uric acid were greater in the hyperuricaemic patients than the controls (5.5"1.04 vs 4.37"0.62, 2.82"2.53 vs 0.78"0.31, and 458.15"101.15 vs 309.4"85, respectively) (P < 0.0001), whereas the plasma levels of HDL cholesterol were lower in the patients (0.92"0.23 vs 1.23"0.27) (P < 0.0001). The body mass index was higher in the patients (27.9"8.7 vs 24.9"3.7) (P < 0.0001).
Apolipoprotein E polymorphisms
The distribution of the apoE genotypes differed betweeen the patients and the controls (P < 0.0001) (Fig. 1) . The most common genotype in the patients was E3u2 (50%), followed by E3u3 (25%), E4u2 (14%) and E4u3 (11%), while the most common in the controls was E3u3(58%), followed by E4u2 (22%), E4u3 (14%) and E3u2 (6%). The frequency of the E2 allele was greater in the patients (64%) than in the controls (28%) (P < 0.0001) Table 2 shows the mean values in the control group of the different variables. There were no significant differences between persons with the E2 allele and those with any other allele of the apoE gene (E3, E4). Urate excretion in gout patients with ApoE2 469 Urate excretion in gout patients with ApoE2 469 Table 3 shows the differences in the biochemical values in the group of patients according to the presence or absence of the E2 phenotype. Patients with the E2 allele had a lower clearance of uric acid than those without the allele (4.2"2.7 vs 6.3"3.3, respectively; P=0.008). Likewise, the excretory fraction of uric acid was also lower (5.5"1.9 vs 7"1.9, respectively; P=0.01). Patients with the E2 allele had higher levels of VLDL triglycerides (1.49"15 vs 0.87"0.51, respectively; P=0.037), and intermediate-density lipoprotein (IDL) triglycerides (0.31"0.29 vs 0.19"0.0087, respectively; P=0.028).
The E4 allele was not associated with any differences in the biochemical parameters studied (data not shown).
Discussion
This study demonstrates that hyperuricaemic patients with gout have a high prevalence of apolipoprotein E2, which is accompanied by increased levels of VLDL and IDL triglycerides and a lower renal excretion of urates. These findings could partly explain the relationship between hyperuricaemia and hyperlipidaemia.
Gout and hyperuricaemia are related to several different conditions, including increased consumption of alcohol, obesity, diabetes, hyperlipaemia, hypertension, renal disease, ischaemic heart disease and the use of diuretics w16-26x. Some of these form part of the metabolic syndrome w27-30x.
The relationship between hyperuricaemia and hyperlipaemia is known. Darlington and Scott w31x found a significant increase in triglycerides, phospholipids and non-esterified fatty acids in hyperuricaemic subjects compared with a control group. BerKowitz w32x and Frank w33x found high levels of triglycerides in 52-82% of patients with gout. In our study, too, the patients had higher levels of triglycerides than the controls, so that 44% of the patients were hyperlipaemic.
Different hypotheses have been proposed to explain this association. These include the action of exogenous factors which together result in hyperuricaemia and hyperlipidaemia. Such factors would include obesity, an increased intake of alcohol, the type of food or some type of genetic factor.
Other authors, however, have found that hypertriglyceridaemia persists in patients with gout after applying a correction factor for body weight. Many studies have demonstrated the existence of hypertriglyceridaemia in patients with gout in the absence of external factors w3, 34x. Moreover, numerous lipoprotein alterations have been found in hyperuricaemic patients, with the most common finding being increased levels of VLDL w35x.
The relationship between hyperuricaemiauhyperlipaemia and renal excretion of urates is also known. Thus, hyperuricaemicuhyperlipaemic patients have a reduced renal excretion of urates compared with patients with just hyperuricaemia w2x. Moreover, in patients with hyperuricaemia there is a close relationship between renal excretion of urates and levels of VLDL w36x. Our group of patients with gout had a high rate of hypertriglyceridaemia and a high prevalence of the E2 allele compared with control subjects from the same area. In the patients with gout who had the E2 allele there were lower levels of renal excretion of urates and an important increase in triglyceride levels, both in VLDL and IDL.
Tinahones et al. w35x demonstrated that hyperuricaemicuhyperlipaemic patients exhibit a considerable reduction in the concentration of triglycerides and VLDL after a low calorie diet, concomitant with an increase in   FIG. 1 . Frequency of the apolipoprotein E genotypes in the two study groups. the renal excretion of uric acid, which reverted with an increase in the VLDL after ceasing the hypocaloric diet, confirming the close relation between VLDL and renal excretion of urates. The role of E2 in the clearance of VLDL is known. ApoE2 has been seen to have a reduced capacity to bind to the remnants receptor (ApoBuE), which would result in a decreased clearance rate and thus lead to differences in lipoprotein levels according to the apoE genotype w37-39x. Sijbrands et al. w40x showed that patients with combined familiar hyperlipaemia, heterozygous for the E2 allele, have significantly higher mean levels of VLDL cholesterol and VLDL triglycerides compared with persons without E2. Rats deficient in ApoE have high levels of ApoAII and this in turn produces an increase in VLDL, resulting in increased levels of triglycerides, cholesterol, ApoB, IDL and LDL and a reduced level of HDL, leading to an increased susceptibility to atherosclerosis. It would thus seem logical to suppose that ApoE plays an important role in the regulation of the levels of these lipoproteins, especially the VLDL w41x. The ApoCIII also seems to be involved, since high concentrations of this apoprotein displace ApoE from VLDL to HDL w42x.
The prevalence of E2 in the metabolic syndrome is known. Its frequency in the Framingham study was 7.8% (n=1916) w43x and in combined familial hyperlipaemia it was 25% compared with 6% in hypercholesterolaemic persons w44, 45x. We found that the prevalence of E2 in patients with hyperuricaemia was greater than in the controls, and probably greater than in the metabolic syndrome. The most prevalent apoE genotype in our hyperuricaemic patients was E3u2, followed by E3u3, E4u2 and E4u3 compared with E3u3, E4u2, E4u3 and E3u2 in the control group.
We conclude that the relationship between hyperuricaemiauhyperlipaemia and renal excretion of urates could be mediated by the high prevalence of the apoE2 allele. Reduced renal excretion of urates has been shown to be accompanied by high levels of VLDL w35x and the E2 isoform of ApoE could contribute to this reduction, since it has already been shown to contribute to high levels of VLDL.
